Search Within

Stephen D Nimer

  1. "Survivorship Research"
Formats
  1. Meeting Abstract (30)
  2. Journal Article (19)
  3. Book Section (1)
Groups
  1. Department of Medicine (50)
  2. Hematologic Malignancies, Division of (50)
  3. Survivorship Research (50)
  4. Center for Hematologic Malignancies (49)
  5. Lymphoma (27)
  6. Radiation Oncology, Department of (27)

More Groups

People
  1. Craig Moskowitz (27)
  2. Joachim Yahalom (27)
  3. Andrew Zelenetz (26)
  4. Tarun Kewalramani (20)
  5. Heather Landau (16)
  6. Hani Hassoun (15)

More People

Years
  1. 2017 (1)
  2. 2012 (3)
  3. 2011 (1)
  4. 2010 (4)
  5. 2009 (6)
  6. 2008 (6)

More Years

Publications
  1. Blood (32)
  2. British Journal of Haematology (4)
  3. Journal of Clinical Oncology (3)
  4. Amyloid (2)
  5. Bone Marrow Transplantation (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (32)
  2. John Wiley & Sons (4)
  3. American Society of Clinical Oncology (3)
  4. Taylor & Francis Group (3)
  5. American Association for Cancer Research (2)
  6. Nature Publishing Group (2)

More Publishers

Results (50)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Risk-adpated high dose chemoradiotherapy and ASCT for patients with relapsed and primary refractory Hodgkin's disease: An intent to treat analysis
    Meeting Abstract

    Moskowitz, C. H.; Kewalramani, T.; Nimer, S. D.; Rice, R. D.; Rosenzweig, L.; Horwitz, S.; Noy, A.; O'connor, O.; Portlock, C. S.; Straus, D.; more...
    Blood (2003)

    Fulltext@MSK | Save
  • Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma
    Journal Article

    Zelenetz, A. D.; Hamlin, P.; Kewalramani, T.; Yahalom, J.; Nimer, S.; Moskowitz, C. H.
    Annals of Oncology (2003)

    Fulltext@MSK | Save
  • Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma
    Journal Article

    Kewalramani, T.; Nimer, S. D.; Zelenetz, A. D.; Malhotra, S.; Qin, J.; Yahalom, J.; Moskowitz, C. H.
    Bone Marrow Transplantation (2003)

    Fulltext@MSK | Save
  • Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
    Journal Article

    Hamlin, P. A.; Zelenetz, A. D.; Kewalramani, T.; Qin, J.; Satagopan, J. M.; Verbel, D.; Noy, A.; Portlock, C. S.; Straus, D. J.; Yahalom, J.; more...
    Blood (2003)

    Fulltext@MSK | Save
  • Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and diffuse large B-cell lymphoma (DLBCL) treated with autologous transplantation (ASCT)
    Meeting Abstract

    Kewalramani, T.; Nimer, S. D.; Zelenetz, A. D.; Hamlin, P. A.; Horwitz, S.; Qin, J.; Malhotra, S.; Yahalom, J.; Moskowitz, C. H.
    Blood (2002)

    Fulltext@MSK | Save
  • Autologous transplantation (ASCT) with total body irradiation (TBI) based conditioning appears superior to chemotherapy only (Non-TBI) conditioning for patients with relapsed or primary refractory chemosensitive (CS) diffuse large B-cell lymphoma (DLBCL) who have no extranodal sits (ENS) of disease (dz)
    Meeting Abstract

    Kewalramani, T.; Moskowitz, C. H.; Zelenetz, A. D.; Malhotra, S.; Qin, J.; Yahalom, J.; Nimer, S. D.
    Blood (2002)

    Fulltext@MSK | Save
  • Phase II study of accelerated fractionation involved field radiotherapy (IFRT), total body irradiation (TBI), ifosfamide and continuous infusion etoposide with autologous stem cell transplantation (ASCT) in the treatment of patients with relapsed and primary refractory aggressive non-Hodgkins lymphoma (NHL)
    Meeting Abstract

    Moskowitz, C. H.; Yahalom, J.; Zelenetz, A. D.; Kewalramani, T.; Malhotra, S.; Nimer, S. D.
    Blood (2001)

    Fulltext@MSK | Save
  • Transcription modulation: A pilot study of sodium phenylbutyrate plus 5-azacytidine
    Meeting Abstract

    Camacho, L. H.; Ryan, J.; Chanel, S.; Maslak, P.; Salomoni, P.; Jakubowski, A.; Klimek, V.; Camastra, D.; Nimer, S.; Pandolfi, P. P.; more...
    Blood (2001)

    Fulltext@MSK | Save
  • Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)
    Meeting Abstract

    Kewalramani, T.; Zelenetz, A.; Bertino, J.; Donnelly, G.; Hedrick, E.; Noy, A.; O'connor, O.; Portlock, C.; Straus, D.; Yahalom, J.; more...
    Blood (2001)

    Fulltext@MSK | Save
  • A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model
    Journal Article

    Moskowitz, C. H.; Nimer, S. D.; Zelenetz, A. D.; Trippett, T.; Hedrick, E. E.; Filippa, D. A.; Louie, D.; Gonzales, M.; Walits, J.; Coady-Lyons, N.; more...
    Blood (2001)

    Fulltext@MSK | Save